Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00984282
Other study ID # 14295
Secondary ID 2009-012007-25
Status Completed
Phase Phase 3
First received
Last updated
Start date October 15, 2009
Est. completion date August 30, 2017

Study information

Verified date August 2018
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine


Description:

Eligible subjects were randomized 1:1 to sorafenib 800 mg daily or matching placebo. Progression was assessed every 8 weeks by modified RECIST criteria. Subjects had the option to unblind study treatment after progression and to receive open label sorafenib regardless of initial treatment assignment. Following discontinuation of study treatment, subjects were followed for survival every 3 months in long-term follow-up. Subjects who terminated study treatment (either double only or double blind and open label) for reasons other than death, lost to follow-up or consent withdrawn entered long-term follow up


Recruitment information / eligibility

Status Completed
Enrollment 417
Est. completion date August 30, 2017
Est. primary completion date August 31, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell)

- Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are eligible provided that the histology has no medullary differentiation nor anaplastic features

- Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors] should be used as a basis for the assessment of disease progression)

- RAI (radioactive iodine) refractory

Exclusion Criteria:

- Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic and medullary carcinoma, lymphoma or sarcoma)

- Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF (vascular endothelial growth factor) or VEGF Receptors or other targeted agents

- Prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose chemotherapy for radiosensitization is allowed) or Thalidomide or any of its derivatives

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sorafenib (Nexavar, BAY43-9006)
Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
Placebo
Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul Seoul Teugbyeolsi

Sponsors (2)

Lead Sponsor Collaborator
Bayer Amgen

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Bulgaria,  China,  Denmark,  France,  Germany,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Russian Federation,  Saudi Arabia,  Spain,  Sweden,  United Kingdom, 

References & Publications (3)

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refrac — View Citation

Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib i — View Citation

Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS. Safety and tolerability of sorafenib in patients with radioiodine-refract — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation PFS=time from randomization to first observed disease progression (radiological according to central assessment or clinical due to bone irradiation, whichever is earlier), or death due to any cause, if death occurred before progression. Progression was assessed by RECIST criteria, version 1.0, modified for bone lesions. PFS for participants without disease progression or death at the time of analysis or unblinding were censored at the last date of tumor assessment before unblinding. Participants with no tumor evaluation after baseline were censored at Day 1. PD (Progression Disease)=At least a 20% increase in sum of longest diameters (LD) of measured lesions taking as reference the smallest sum LD on study since the treatment started or the appearance of 1 or more new lesions. New lesions also constituted PD. In exceptional circumstances, unequivocal progression of a nonmeasured lesion may have been accepted as evidence of disease progression in participants with measurable disease. Final analysis to be performed when approximately 267 progression-free survival events (centrally assessed) had occurred, study duration approximately three years
Secondary Overall Survival (OS) Overall survival was defined as the time (days) from date of randomization to date of death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Since the median value could not be estimated due to censored data, the percentage of participants who died is presented. From randomization of the first subject until the database cut-off (30 AUG 2017), study duration approximately eight years
Secondary Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation Time to progression was defined at the time (days) from randomization to progression (based on central assessment [radiological and clinical progression due to bone irradiation]) From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
Secondary Disease Control Rate (DCR) Based on Central Assessment Disease control rate was defined as the proportion of subjects whose best response was complete response (CR), partial response (PR), or stable disease (SD). Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, CR and PR were to be confirmed by another scan at least 4 weeks later; SD had to be documented at least 4 weeks after date of randomization. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. SD = steady state of disease which is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
Secondary Response Rate Based on Central Assessment Response rate was defined as the proportion of subjects whose best response was CR or PR. Per RECIST, CR and PR was to be confirmed by another scan at least 4 weeks later. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
Secondary Duration of Response (DOR) Based on Central Assessment Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
Secondary Maximum Percent Reduction in Target Lesion Size Based on Central Assessment The magnitude of change from baseline in target lesion size in evaluable participants with scans was determined. From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
Secondary AUC(0-12h),ss (Area Under the Concentration Time Curve From Time 0 to 12 Hours at Steady State) Sorafenib AUC(0-12h),ss (area under the concentration time curve from time 0 to 12 hours at steady state) was estimated from the steady state plasma concentration. A single pharmacokinetic plasma sample was collected at steady state (after 14 days of uninterrupted, unmodified sorafenib dosing)
See also
  Status Clinical Trial Phase
Completed NCT00537095 - Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Phase 2
Recruiting NCT04139096 - Genetic Susceptibility to Radiation Induced Thyroid Cancer
Completed NCT00754182 - Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision N/A
Completed NCT00094055 - Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Phase 2
Completed NCT00148213 - Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma N/A
Recruiting NCT06398795 - Dual-port Trans-subclavian Thyroid Endoscopic Surgery N/A
Recruiting NCT01005654 - Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Active, not recruiting NCT05579782 - Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A
Completed NCT01437254 - To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer Phase 1
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT01292044 - The Role of Elastography in the Diagnosis of Thyroid Nodules N/A
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Active, not recruiting NCT02418247 - Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Phase 2/Phase 3
Completed NCT00467506 - Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Phase 2
Completed NCT02430714 - Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Recruiting NCT04410601 - Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Completed NCT03871387 - The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change N/A